网络出版日期: 2021-08-03
基金资助
上海市科学技术委员会“科技创新行动计划”(17441903600);上海市耳鼻疾病转化医学重点实验室(14DZ2260300)
Natural history and symptom evolution of acoustic neuroma: an analysis of 56 patients
Online published: 2021-08-03
Supported by
Innovation Action Plan of Science and Technology Committee of Shanghai Municipality(17441903600);Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases(14DZ2260300)
目的·初步观察中国人群散发性听神经瘤的中短期自然生长速度及其与临床特征的关系。方法·回顾性分析2016年3月至2019年11月在上海交通大学医学院附属第九人民医院耳鼻咽喉头颈外科就诊及随访复诊的散发性听神经瘤患者;要求纳入研究的患者至少有2次增强磁共振的数字资料且首末2次间隔时间>60 d。收集患者的增强磁共振DICOM资料、听力学资料(纯音听阈及言语识别率)、临床表现(听力下降、耳鸣、眩晕、面部疼痛或麻木)等。通过HorosTM软件载入影像学数据,进行肿瘤大小的测量,并计算肿瘤生长速度。随后对肿瘤的生长速度与临床表现进行关联性分析。结果·共有56例患者纳入研究,男、女各28例,平均年龄(48.6±12.0)岁,初诊时肿瘤最大径为(15.9±9.6)mm,2次磁共振检查的间隔时间为(266.3±313.5)d,总体肿瘤生长速度为(4.4±4.7)mm/a;其中8例囊性变肿瘤的生长速度显著快于余48例非囊性变[(9.4±3.8)mm/a vs (3.6±4.4)mm/a,P=0.003]。在非囊性变肿瘤患者中,初诊时22例内听道内型和小型(≤10 mm)肿瘤相对其他肿瘤的生长速度较慢[(2.1±3.6)mm/a vs (4.8±4.7)mm/a,P=0.031];60岁及以上患者的肿瘤生长速度显著慢于60岁以下的患者[(1.7±3.1)mm/a vs (4.2±4.6)mm/a,P=0.040]。主动采用随访策略者中,58.8%患者肿瘤稳定,81.8%有可测听力者未出现听力分级下降。有无突聋、耳鸣或眩晕史的患者间,初诊时不同听力分级患者间,不同性别、患侧的患者间的肿瘤生长速度差异均无统计学意义(均P>0.05)。结论·囊性变听神经瘤生长迅速,需积极治疗;内听道内型和小型(≤10 mm)非囊性变患者,以及60岁及以上患者肿瘤生长较为缓慢;符合影像学观察随访策略的患者在1年内可基本维持原有听力水平。
姚俊吉 , 陈见清 , 谭皓月 , 汪照炎 , 张治华 , 吴皓 , 贾欢 . 听神经瘤自然生长规律与症状演变的初步分析:56例患者回顾[J]. 上海交通大学学报(医学版), 2021 , 41(7) : 898 -902 . DOI: 10.3969/j.issn.1674-8115.2021.07.008
·To preliminarily observe the natural history of the sporadic acoustic neuroma and its relationship with clinical manifestations in Chinese population.
·From March 2016 to November 2019, the patients with sporadic acoustic neuroma who had visit and follow-up in the Department of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine were analyzed retrospectively. The patients included in the study were required to have at least two digital data of enhanced MRI, and the interval between the first and the last time was more than 60 d. Their radiological DICOM data (enhanced MRI), audiological reports (pure tone average threshold and speech discrimination score), and clinical manifestations (hearing loss, tinnitus, vertigo, and facial pain or numbness) were collected. Image data were loaded by HorosTM software to measure tumor size and calculate tumor growth rate. Then the relationship between tumor growth rate and clinical manifestations was analyzed.
·A total of 56 patients were included, 28 males and 28 females, with the average age of (48.6±12.0) years old. Their initial tumor size was (15.9±9.6) mm in the maximum diameter, and the mean interval between the two times of MRI was (266.3±313.5) d. The average growth rate was (4.4±4.7) mm/a. Eight cystic tumors grew more rapidly than non-cystic ones [(9.4±3.8) mm/a vs (3.6±4.4) mm/a, P=0.003). Among the 48 non-cystic acoustic neuromas, 22 internal auditory canal type and small (≤10 mm) tumors grew more slowly than other tumors [(2.1±3.6) mm/a vs (4.8±4.7) mm/a, P=0.031]; the tumors grew more slowly in the patients with the ages of 60 years or above than those in the patients younger than 60 years old [(1.7±3.1) mm/a vs (4.2±4.6) mm/a, P=0.040]. 58.8% of the patients undergoing active “wait and scan” strategy had stable tumors, and 81.8% patients with measurable hearing did not show hearing deterioration during their follow-up. Other factors like sudden deafness, tinnitus, vertigo, initial hearing level, sex, and tumor side had no correlations with tumor growth rate (all P>0.05).
·Cystic sporadic acoustic neuroma is confirmed as a rapid growth tumor, which needs active treatment. The tumors grow slowly in the non-cystic acoustic neuromas which are internal auditory canal type, not bigger than 10 mm or in the patients aged 60 years and above. The cases that are suitable for “wait and scan” policy can basically maintain their original hearing level during one year.
1 | Nikolopoulos TP, Fortnum H, O'Donoghue G, et al. Acoustic neuroma growth[J]. Otol Neurotol, 2010, 31(3): 478-485. |
2 | Stangerup SE, Caye-Thomasen P, Tos M, et al. The natural history of vestibular schwannoma[J]. Otol Neurotol, 2006, 27(4): 547-552. |
3 | Flickinger JC, Kondziolka D, Niranjan A, et al. Results of acoustic neuroma radiosurgery: an analysis of 5 years′ experience using current methods[J]. J Neurosurg, 2001, 94(1): 1-6. |
4 | Raut VV, Walsh RM, Bath AP, et al. Conservative management of vestibular schwannomas: second review of a prospective longitudinal study[J]. Clin Otolaryngol Allied Sci, 2004, 29(5): 505-514. |
5 | Fucci MJ, Buchman CA, Brackmann DE, et al. Acoustic tumor growth: implications for treatment choices[J]. Am J Otol, 1999, 20(4): 495-499. |
6 | Bozorg Grayeli A, Kalamarides M, Ferrary E, et al. Conservative management versus surgery for small vestibular schwannomas[J]. Acta Otolaryngol, 2005, 125(10): 1063-1068. |
7 | Patnaik U, Prasad SC, Tutar H, et al. The long-term outcomes of wait-and-scan and the role of radiotherapy in the management of vestibular schwannomas[J]. Otol Neurotol, 2015, 36(4): 638-646. |
8 | 孙时斌, 刘阿力, 罗斌, 等. 伽玛刀治疗听神经鞘瘤的MRI随访及临床分析[J]. 中华放射学杂志, 2004, 38(10): 1042-1046. |
9 | 火子榕, 张治华, 黄琦, 等. 唯一听力耳听神经瘤患者人工耳蜗植入疗效分析[J]. 中华耳鼻咽喉头颈外科杂志, 2016, 51(6): 408-413. |
10 | Lassaletta L, Aristegui M, Medina M, et al. Ipsilateral cochlear implantation in patients with sporadic vestibular schwannoma in the only or best hearing ear and in patients with NF2[J]. Eur Arch Otorhinolaryngol, 2016, 273(1): 27-35. |
11 | Hitselberger WE, House WF. Classification of acoustic neuromas: supplement to the monograph on transtemporal bone microsurgical removal of acoustic neuromas[J]. Arch Otolaryngol, 1966, 84(3): 245-246. |
12 | Samii M, Matthies C. Management of 1 000 vestibular schwannomas (acoustic neuromas): surgical management and results with an emphasis on complications and how to avoid them[J]. Neurosurgery, 1997, 40(1): 11-21, discussion 21-23. |
13 | 中华耳鼻咽喉头颈外科杂志编辑委员会, 中华医学会耳鼻咽喉头颈外科学分会. 听神经瘤诊断和治疗建议[J]. 中华耳鼻咽喉头颈外科杂志, 2014, 49(3): 181-186. |
14 | Huo ZR, Zhang ZH, Huang Q, et al. Clinical comparison of two subtypes of cystic vestibular schwannoma: surgical considerations and outcomes[J]. Eur Arch Otorhinolaryngol, 2016, 273(12): 4215-4223. |
15 | Koos WT, Day JD, Matula C, et al. Neurotopographic considerations in the microsurgical treatment of small acoustic neurinomas[J]. J Neurosurg, 1998, 88(3): 506-512. |
16 | Paldor I, Chen AS, Kaye AH. Growth rate of vestibular schwannoma[J]. J Clin Neurosci, 2016, 32: 1-8. |
17 | Rosenberg SI. Natural history of acoustic neuromas[J]. Laryngoscope, 2000, 110(4): 497-508. |
18 | Jethanamest D, Rivera AM, Ji H, et al. Conservative management of vestibular schwannoma: predictors of growth and hearing[J]. Laryngoscope, 2015, 125(9): 2163-2168. |
19 | Stangerup SE, Caye-Thomasen P. Epidemiology and natural history of vestibular schwannomas[J]. Otolaryngol Clin North Am, 2012, 45(2): 257-268, vii. |
20 | Carlson ML, Vivas EX, McCracken DJ, et al. Congress of neurological surgeons systematic review and evidence-based guidelines on hearing preservation outcomes in patients with sporadic vestibular schwannomas[J]. Neurosurgery, 2018, 82(2): E35-E39. |
21 | Preet K, Ong V, Sheppard JP, et al. Postoperative hearing preservation in patients undergoing retrosigmoid craniotomy for resection of vestibular schwannomas: a systematic review of 2 034 patients[J]. Neurosurgery, 2020, 86(3): 332-342. |
22 | Zhu WD, Chen HS, Jia H, et al. Long-term hearing preservation outcomes for small vestibular schwannomas: retrosigmoid removal versus observation[J]. Otol Neurotol, 2018, 39(2): e158-e165. |
/
〈 |
|
〉 |